Phase I Trial of Intraperitoneal Nab-Paclitaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

null null Aim: The primary objective was to determine maximum tolerated dose (MTD) and the potential PK advantage of IP nab-paclitaxel (favorable peritoneal cavity ratio of nab-paclitaxel: plasma). null Methods: Phase I study of IP nab-paclitaxel, D1, 8, 15; 28-day cycle; 3 + 3 dose-escalation design in patients (pts) with advanced ovarian cancer primarily confined to the peritoneal cavity, unresponsive to previous regimens, or for which no...